Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CDK9 | P50750 | 6/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634234 | 0.89 | JAK3 (0.42) | LRRK2SYKCDK2CDK9EGFR | |
| SCHEMBL2469935 | 0.88 | LRRK2 (0.44) | LRRK2GAKSYKCDK2CDK9 | |
| SCHEMBL14633989 | 0.85 | SYK (0.42) | LRRK2GAKSYKCDK2CDK9 | |
| SCHEMBL14633512 | 0.84 | ADORA3 (0.48) | LRRK2GAKSYKCDK2CDK9 | |
| SCHEMBL14634077 | 0.82 | JAK1 (0.40) | LRRK2GAKSYKCDK2CDK9 | |
| SCHEMBL14633954 | 0.79 | JAK3 (0.42) | LRRK2SYKCDK2CDK9EGFR | |
| SCHEMBL2468378 | 0.78 | CDK1 (0.39) | SYKCDK2CDK9EGFRITK | |
| SCHEMBL2468022 | 0.77 | JAK2 (0.49) | CDK2CDK9CCNT1 | |
| SCHEMBL14633759 | 0.77 | GRM4 (0.44) | LRRK2SYKCDK2CDK9EGFR | |
| SCHEMBL14634112 | 0.76 | GRM4 (0.52) | LRRK2GAKITKGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | LRRK2 487/4885GAK 237/4885SYK 409/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | LRRK2 599/4885GAK 85/4885SYK 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.